scholarly journals A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development

2011 ◽  
Vol 1 (1) ◽  
Author(s):  
Benoît Malleret ◽  
Carla Claser ◽  
Alice Soh Meoy Ong ◽  
Rossarin Suwanarusk ◽  
Kanlaya Sriprawat ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Malaria Parasite ◽  
Parasite Development ◽  
Flow Cytometry Assay ◽  
Color Flow

A Single Tube, Four-Color Flow Cytometry Assay for Evaluation of ZAP-70 and CD38 Expression in Chronic Lymphocytic Leukemia

2010 ◽  
Vol 133 (5) ◽  
pp. 708-717 ◽  
Author(s):  
Nagwa M. Hassanein ◽  
Kathryn R. Perkinson ◽  
Felisa Alcancia ◽  
Barbara K. Goodman ◽  
J. Brice Weinberg ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Flow Cytometry Assay ◽  
Color Flow ◽  
Single Tube ◽  
Cd38 Expression

scholarly journals Validation of a Sensitive Flow Cytometry Assay to Assess Minimal Residual Disease of Multiple Myeloma Cells in Apheresis Product

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5646-5646
Author(s):  
Nicholas Jones ◽  
Josette William Ragheb ◽  
Brian Ngo ◽  
David Uyeji ◽  
Anselm L. Hii
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Stem Cell ◽  
Minimal Residual Disease ◽  
Patient Monitoring ◽  
Residual Disease ◽  
Cell Transplant ◽  
Flow Cytometry Assay ◽  
Color Flow ◽  
Minimal Residual

Abstract For treatment of patients with multiple myeloma (MM), flow cytometry has become a widely used and valuable method for the evaluation of minimal residual disease (MRD) in bone marrow. Use of an optimized single-tube, 10-color flow cytometry panel for assessment of MM MRD has shown to be beneficial in patient monitoring and has shown correlation to the acknowledged EuroFlow 8-color, 2-tube method. In order to further correlate levels of MM and relapse in patients, validation of a sensitive MM MRD assay that can be applied to testing for residual disease in apheresis product prior to autologous stem cell transplant, a standard treatment for patients with multiple myeloma. This approach can exhibit great value in patient monitoring and treatment. As new combination therapies are developed for treatment of multiple myeloma in concert with autologous stem cell transplantation, evaluation of MRD in apheresis will likely continue to grow in importance. The purpose of this study is to show the validation and sensitivity of a flow cytometry assay designed to detect Multiple Myeloma (MM) cells in G-CSF and other mobilized apheresis samples from human Multiple Myeloma patients. Using GSM-mobilized apheresis product, spiked with different levels of patient de-identified MM plasma cells, validation of a 10-color MM MRD panel can be evaluated, intended to mimic patient apheresis at varying levels of residual disease post treatment. As with any minimal residual disease assessment, a high number of events are required to ensure sensitivity and precision. Typically, acquisition of 3-5 x 107 events is required to ensure precision of MM MRD levels to 0.001%. Disclosures No relevant conflicts of interest to declare.

scholarly journals A modified two-color flow cytometry assay to quantify in-vitro reinvasion and determine invasion phenotypes at low Plasmodium falciparum parasitemia

2020 ◽  
Vol 218 ◽  
pp. 107969
Author(s):  
Ines Atuh Ngoh ◽  
Damian Nota Anong ◽  
Jerome Cho Fru ◽  
Fatoumata Bojang ◽  
Haddijatou Mbye ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Plasmodium Falciparum ◽  
Flow Cytometry Assay ◽  
Color Flow

Whole Spleen Flow Cytometry Assay

BIO-PROTOCOL ◽  
2013 ◽  
Vol 3 (15) ◽  
Author(s):  
Cathy Yam ◽  
Adeline Hajjar
Keyword(s):  
Flow Cytometry ◽  
Flow Cytometry Assay
Sign in / Sign up

Export Citation Format

Share Document